Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Ceryvyn Outlines LAM Drug Development Focus as Shares Fall 9%

CYV: $0.010 -9.09% · MC: $12M

Ceryvyn Therapeutics’ November investor presentation highlights CYV-101, an investigational fusion protein it intends to test in lymphangioleiomyomatosis, a rare lung disease; the excerpt provides no new clinical or financial guidance. Shares fell around 9% on the day, alongside the presentation.

Source announcements: 2026-11-17 16:10 to 2026-11-17 16:10 Sydney time
Story updated 2026-11-17 16:14 Sydney time
SourcesInvestor Presentation
Comments